Oro therapeutics
Developing peptide-drug conjugates (PDCs) to exploit the distinct enzymatic properties of cancer cells.
Oro therapeutics
Developing peptide-drug conjugates (PDCs) to exploit the distinct enzymatic properties of cancer cells.
Oncology pipelines are dominated by immunotherapy-based MoAs
However, there remains an unmet medical need for MoAs that don’t rely on the patient’s immune system
Patients
•Immunosenescent patients, patients with co-morbidities, elderly patients, or frail patients
•Patients at risk for CRS* or ICANS*
Providers
•Oncologists want options for patients deemed not appropriate for Immunotherapy, or who have progressed following Immunotherapy treatment
•Want off-the-shelf solutions
Sites of care
•Majority of cancer patients in the US are treated in the community setting, which don’t have inpatient facilities and specialized technologies needed for patient monitoring during immunotherapy administration
* CRS = “Cytokine Release Syndrome, ICANS = Immune effector-cell associated neurotoxicity syndrome
About Oro Therapeutics
Our Mission
As the treatment landscape for hematological malignancies advances, especially with the growing prominence of cell and gene therapies, a substantial unmet need persists for innovative mechanisms of action (MoAs) and therapies that can address the unique challenges of treating elderly or frail patients. These patients are typically not suitable candidates for the more aggressive treatments typically reserved for "fit" patients. Our mission is to bridge this gap by delivering effective, accessible treatment options specifically designed to meet the needs of this underserved population in community settings.